Lucentis® receives positive opinion

Novartis has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Lucentis® (ranibizumab) to treat patients with visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (myopic CNV).
Source: Pharmacy Europe - Category: Drugs & Pharmacology Source Type: news